Monte Competitors

Stocks . USA . 
Stock . Monte Rosa Therapeutics
GLUE Stock  USD 17.75  0.75  4.05%   
Monte Rosa Therapeutics competes with Day One, Arvinas, Replimune, Theravance Biopharma, and ArriVent BioPharma; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Monte Rosa competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Monte Rosa to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Monte Rosa Correlation with its peers.

Monte Rosa vs MeiraGTx Holdings Correlation

Very good diversification

The correlation between Monte Rosa Therapeutics and MGTX is -0.44 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Monte Rosa Therapeutics and MGTX in the same portfolio, assuming nothing else is changed.

Moving together with Monte Stock

  0.668VP1 AVRICORE HEALTH INCPairCorr

Moving against Monte Stock

  0.42ALSEN Sensorion SAPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Monte Rosa's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
10.1517.4424.73
Details
Intrinsic
Valuation
LowRealHigh
13.9721.2628.55
Details
Naive
Forecast
LowNextHigh
13.8421.1328.42
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
17.7517.7517.75
Details

Monte Rosa Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Monte Rosa and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Monte and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Monte Rosa Therapeutics does not affect the price movement of the other competitor.

High positive correlations

VALN
+ 0.73
GERN
VIR
+ 0.72
GERN
VALN
+ 0.71
VIR
TBPH
+ 0.69
DAWN
MGTX
+ 0.67
REPL
VALN
+ 0.66
DAWN
  

High negative correlations

REPL
- 0.79
DAWN
TBPH
- 0.6
REPL
VALN
- 0.59
REPL
MGTX
- 0.5
DAWN
MGTX
- 0.49
VALN
VIR
- 0.48
REPL

Risk-Adjusted Indicators

There is a big difference between Monte Stock performing well and Monte Rosa Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Monte Rosa's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
DAWN  3.99  0.51  0.11 (1.51) 3.49 
(5.54)
 11.23 
(6.53)
 35.80 
ARVN  2.55  0.16  0.06  0.21  2.74 
(3.06)
 5.48 
(3.75)
 18.21 
REPL  2.90 (0.27) 0.00 (0.28) 0.00 
 0.00 
 6.34 
(6.22)
 20.74 
TBPH  1.81 (0.06)(0.03) 0.00  2.47 
(1.72)
 3.46 
(3.99)
 11.40 
AVBP  2.71  0.21  0.05  0.69  2.84 
(3.56)
 6.71 
(4.81)
 18.12 
GERN  3.07  0.55  0.16  0.39  3.12 
(4.07)
 8.59 
(4.29)
 24.20 
VIR  3.87  0.70  0.21  0.47  3.41 
(4.81)
 8.13 
(6.80)
 34.53 
DNA  4.02 (0.43) 0.00 (0.02) 0.00 
 0.00 
 8.31 
(6.79)
 30.46 
VALN  2.68  0.38  0.12  0.69  2.58 
(3.11)
 5.63 
(4.84)
 15.59 
MGTX  2.47 (0.05)(0.01) 0.04  3.04 
(2.54)
 5.08 
(5.54)
 16.37 

Monte Rosa Competitive Analysis

The better you understand Monte Rosa competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Monte Rosa's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Monte Rosa's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
GLUE DAWN ARVN REPL TBPH AVBP GERN VIR DNA VALN
 4.05 
 17.75 
Monte
 0.47 
 10.60 
Day
 0.82 
 13.27 
Arvinas
 0.52 
 7.65 
Replimune
 0.33 
 18.25 
Theravance
 1.12 
 22.97 
ArriVent
 1.82 
 1.68 
Geron
 2.47 
 9.09 
Vir
 30.48 
 6.75 
Ginkgo
 1.37 
 11.09 
Valneva
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Slightly risky
Not too volatile
Slightly risky
Very steady
Not too volatile
Very risky
Slightly risky
Moderately volatile
Somewhat reliable
Market Performance
(90 Days Performance)
Soft
Mild
Mild
Weakest
Weakest
Weak
Good
Good
Weakest
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
High
Low
Average
Low
High
Moderate
Small
Risky
Small
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Buy
Hold
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Sell
Hold
Strong Sell
Hold
Hold
Sell
Hold
Current Ratio
20.11
31.45
5.33
19.79
4.74
N/A
4.85
4.79
11.84
1.15
Net Asset
438.73 M
507.83 M
717.9 M
551.33 M
354.16 M
274.94 M
570.54 M
1 B
1.12 B
500.03 M
Profit Margin
0.12
-0.68
-0.31
N/A
0.37
N/A
-0.47
N/A
-1.84
-0.57
EBITDA
(72.99 M)
(105.82 M)
(75.3 M)
(253.92 M)
(38.45 M)
(80.49 M)
(53.84 M)
(426.09 M)
(254.61 M)
32.08 M
Operating Margin
-2.58
-0.51
-7.55
N/A
-0.32
N/A
-0.22
-0.75
-1.97
-1.27
Current Valuation
999.93 M
638.65 M
74.28 M
438.89 M
635.63 M
646.78 M
813.82 M
859.7 M
369.99 M
1.03 B
Price To Book
5.5
2.41
1.51
3.0
3.96
3.1
4.31
1.59
0.73
5.4
Retained Earnings
(438.59 M)
(661.4 M)
(1.61 B)
(948.58 M)
(965.52 M)
(238.33 M)
(1.77 B)
(1.2 B)
(6.15 B)
(563.93 M)
Current Asset
N/A
N/A
80.17 M
N/A
237.47 M
N/A
115.89 M
N/A
10.07 B
N/A
Beta
1.62
-1.26
1.88
0.75
0.16
1.03
0.62
1.69
1.56
1.2
Number Of Employees
147
178
430
479
97
52
229
367
834
713
Shares Outstanding
76.24 M
102.68 M
64.22 M
82.57 M
50.67 M
41.28 M
638.36 M
139.13 M
48.52 M
86.88 M
Cash Flow From Operations
42 M
(103.76 M)
(273.8 M)
(192.25 M)
(11.54 M)
(70.21 M)
(218.62 M)
(391.78 M)
(171.06 M)
(67.22 M)
Total Debt
42.72 M
2.79 M
8.5 M
76.17 M
49.82 M
176 K
346.95 M
186.91 M
417.08 M
216.31 M
Return On Equity
0.0928
-0.23
-0.16
-0.91
0.14
-0.52
-0.34
-0.46
-0.51
-0.56
Return On Asset
0.0137
-0.15
-0.0794
-0.43
-0.0532
-0.33
-0.0578
-0.24
-0.15
-0.0964
Number Of Shares Shorted
9.33 M
10.28 M
4.05 M
15.53 M
4.52 M
7.05 M
65.03 M
12.78 M
7.26 M
139.31 K
Book Value Per Share
3.98
4.28
6.83
2.64
4.59
7.47
0.34
5.49
8.21
0.98
Current Liabilities
N/A
N/A
15.89 M
N/A
49.47 M
N/A
6.63 M
N/A
3.1 B
N/A
Total Asset
438.73 M
507.83 M
717.9 M
551.33 M
354.16 M
274.94 M
570.54 M
1 B
1.12 B
500.03 M
Debt To Equity
0.16
0.002
0.009
0.079
652.2
N/A
0.39
0.068
0.032
1.43
Short Ratio
8.35
3.89
5.22
11.33
12.28
14.06
4.91
6.88
6.56
10.94
Target Price
33.8
22.75
14.25
12.86
26.71
40.25
3.4
20.22
10.0
13.1
Shares Owned By Institutions
95.24
79.59
86.64
97.4
99.34
96.88
76.55
86.22
74.77
6.05
Market Capitalization
1.35 B
1.09 B
974.25 M
631.68 M
924.77 M
948.23 M
1.07 B
1.26 B
408.98 M
963.46 M
Price To Earning
1.91
3.88
-0.45
N/A
-6.2
N/A
-12.48
3.16
25.51
N/A
Price To Earnings To Growth
N/A
N/A
0.28
N/A
-0.05
N/A
-2.38
1.14
N/A
N/A
Price To Sales
7.45
6.88
3.71
N/A
11.51
N/A
5.83
18.45
2.4
5.36
Net Income
(72.7 M)
(107.32 M)
(80.8 M)
(247.3 M)
(56.42 M)
(80.49 M)
(174.57 M)
(437.99 M)
(312.76 M)
(12.25 M)
Earnings Per Share
0.32
-1.52
-0.81
-3.44
0.57
-4.15
-0.12
-3.62
-6.18
-1.54
Shares Owned By Insiders
0.81
16.87
7.9
2.18
3.71
3.12
0.1
10.53
3.46
N/A
Revenue
75.62 M
158.18 M
262.6 M
N/A
64.38 M
N/A
183.88 M
68.56 M
170.16 M
169.58 M
Working Capital
220.49 M
488.88 M
837.5 M
433.52 M
128.98 M
209.71 M
402.69 M
922.8 M
495.48 M
184.43 M
Cash And Equivalents
294.14 M
394.86 M
1.27 B
395.08 M
132.85 M
N/A
219.29 M
2.2 B
561.57 M
336.22 M
Cash Per Share
6.32
5.38
23.87
8.01
1.74
N/A
0.58
16.55
0.84
5.74
Gross Profit
50.97 M
140.97 M
262.6 M
N/A
40.82 M
N/A
105.42 M
(375.95 M)
123.18 M
(3.69 M)
Day Typical Price
17.84
10.58
13.23
7.65
18.12
23.07
1.68
9.16
7.23
11.08
Accumulation Distribution
0.04
0.0234
0.0386
0.0309
0.0375
0.0378
0.08
0.0642
0.19
0.0188
Market Facilitation Index
0.73
0.25
0.52
0.24
0.69
0.89
0.14
0.61
1.59
0.21
Daily Balance Of Power
(1.03)
(0.20)
(0.21)
(0.17)
0.087
(0.29)
0.2143
(0.38)
(1.86)
0.7143
Period Momentum Indicator
(0.75)
(0.05)
(0.11)
(0.04)
0.06
(0.26)
0.03
(0.23)
(2.96)
0.15
Rate Of Daily Change
0.96
1.0
0.99
0.99
1.0
0.99
1.02
0.98
0.7
1.01
Day Median Price
17.88
10.57
13.21
7.65
18.06
23.12
1.68
9.2
7.48
11.08
Price Action Indicator
(0.51)
0.01
0.005
(0.02)
0.22
(0.28)
0.015
(0.22)
(2.20)
0.09
Relative Strength Index
14.37
26.58
31.77
16.01
6.32
21.4
16.03
56.76
14.36
35.18
Coefficient Of Variation
1763.64
1201.78
1219.81
(2,000)
29881.87
1467.55
590.91
651.68
(7,319)
769.47
Mean Deviation
4.05
3.99
2.55
2.9
1.81
2.71
3.07
3.87
4.02
2.68
Jensen Alpha
0.2885
0.5063
0.1572
(0.27)
(0.06)
0.2107
0.5483
0.7037
(0.43)
0.3779
Total Risk Alpha
(0.36)
(0.13)
(0.08)
(0.63)
(0.25)
(0.14)
0.2581
0.2647
(0.74)
0.0761
Sortino Ratio
0.0776
0.1084
0.0605
N/A
(0.03)
0.0534
0.1601
0.2051
N/A
0.1244
Downside Variance
17.38
13.67
8.51
N/A
6.54
8.79
14.5
14.07
N/A
7.81
Standard Deviation
7.29
5.9
3.25
4.01
2.33
3.64
4.13
5.6
6.21
3.37
Kurtosis
23.65
6.33
0.6939
1.21
0.0932
0.8333
1.35
7.55
9.51
0.2934
Potential Upside
9.41
11.23
5.48
6.34
3.46
6.71
8.59
8.13
8.31
5.63
Treynor Ratio
0.2804
(1.51)
0.2066
(0.28)
(0)
0.6921
0.3901
0.4663
(0.02)
0.6888
Maximum Drawdown
53.94
35.8
18.21
20.74
11.4
18.12
24.2
34.53
30.46
15.59
Variance
53.16
34.8
10.56
16.1
5.42
13.27
17.09
31.35
38.59
11.33
Market Risk Adjusted Performance
0.2904
(1.50)
0.2166
(0.27)
0.0067
0.7021
0.4001
0.4763
(0.01)
0.6988
Risk Adjusted Performance
0.0524
0.0724
0.0704
(0.03)
0.0093
0.0601
0.1377
0.1261
(0)
0.1072
Skewness
4.03
2.04
0.0563
0.5449
(0.14)
0.496
0.2122
1.95
(1.15)
0.5572
Semi Deviation
3.77
3.49
2.74
N/A
2.47
2.84
3.12
3.41
N/A
2.58
Information Ratio
0.0444
0.068
0.0543
(0.07)
(0.04)
0.0435
0.1475
0.1374
(0.03)
0.1033
Value At Risk
(6.69)
(6.53)
(3.75)
(6.22)
(3.99)
(4.81)
(4.29)
(6.80)
(6.79)
(4.84)
Expected Short fall
(5.04)
(5.54)
(3.06)
N/A
(1.72)
(3.56)
(4.07)
(4.81)
N/A
(3.11)
Downside Deviation
4.17
3.7
2.92
N/A
2.56
2.96
3.81
3.75
N/A
2.79
Semi Variance
14.22
12.15
7.52
N/A
6.1
8.09
9.76
11.64
N/A
6.68

Monte Rosa Competition Performance Charts

Five steps to successful analysis of Monte Rosa Competition

Monte Rosa's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Monte Rosa Therapeutics in relation to its competition. Monte Rosa's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Monte Rosa in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Monte Rosa's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Monte Rosa Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Monte Rosa position

In addition to having Monte Rosa in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Penny Thematic Idea Now

Penny
Penny Theme
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
How To Invest In Monte
Details
Is Monte Stock a good investment?
Details
What is Monte Rosa's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Monte Rosa Correlation with its peers.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY